HURA — TuHURA Biosciences, Inc./NV

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1498382 ·
Last close
$1.40
Market Cap
$89.22M
52W High
$3.43
52W Low
$0.41
ADV30
460,485
Next earnings
2026-11-13
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -5,660,761 -6,409,585 36,243,594 1,894,351 17,290,070
Jun 2026 0 — -8,763,284 -9,223,298 31,746,253 995,977 13,245,793
Mar 2026 0 — -7,529,899 -7,536,598 29,704,779 6,298,127 6,514,898
Dec 2025 0 — -4,380,165 -6,761,316 27,353,156 3,619,949 6,420,828

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-29,689,118
Investing CF
$-213,674
Financing CF
$22,385,945
CapEx
$-219,235
Dividends Paid
$-8,356
Buybacks
—
EPS Diluted TTM
$-0.62
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-157,948,976
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-29,502,776
Pretax Income TTM
$-30,623,667
Interest Exp TTM
$1,120,891
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -27,289,239 -30,051,977 27,353,156 6,420,828 20,932,328 -27,629,150
Dec 2024 0 -17,151,525 -21,682,306 19,966,684 5,372,708 14,593,976 -14,728,138
Dec 2023 0 -13,170,156 -29,316,826 4,361,791 5,920,537 -1,558,746 -11,950,856
Dec 2022 0 -9,718,934 -9,367,513 15,196,608 2,892,667 12,303,941 -7,508,259

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-30,623,667
OpCashFlow TTM
—
Assets (Latest)
$31,746,253
Forward EPS
$-0.62

Peers — same industry

TickerNameMarket CapLastDaily %
NKTX Nkarta, Inc. $89.53M $1.25 —
GNLX GENELUX Corp $90.49M $2.00 —
CPIX CUMBERLAND PHARMACEUTICALS INC $86.96M $5.80 —
RVRC Revium Rx. $86.84M $1.43 —
DERM Journey Medical Corp $86.70M $3.90 —

News headlines (Yahoo Finance, 1h cache)

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-13 12:45 · Yahoo
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
2026-11-04 14:15 · Yahoo
HURA: First Look at IFx-2.0 Deep-Seated Tumors
2026-11-03 12:00 · Yahoo
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
2026-10-26 20:02 · Yahoo
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Ca
2026-10-26 11:30 · Yahoo
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
2026-10-13 11:45 · Yahoo
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
2026-10-05 11:45 · Yahoo
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related
2026-09-14 11:45 · Yahoo
HURA: Milestone Progression Over Next 12 Months
2026-08-26 09:12 · Yahoo
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord
2026-08-14 15:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.